Physician profile
Collin Rush
NPI 1437509007
$1,626.99
in general payments reported to CMS, 2019-2025
14 companies · $166 in 2025
The $166 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336 · 2020: $828 · 2021: $41.46 · 2022: $11.68 · 2023: $197 · 2024: $47.76 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $372 · Entertainment: $38.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $371.80 |
| Entertainment | $38.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $898.16 | 2019-2020 | |
| Alcon Vision LLC | $220.67 | 2019-2025 | Wavelight Refractive Suite, Dailies Total1, Total30 |
| Optos, INC. | $170.12 | 2019-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Tarsus Pharmaceuticals, INC. | $89.24 | 2025 | Xdemvy |
| Lombart Brothers, INC. | $84.39 | 2019-2024 | Opd-III |
| Allergan, INC. | $41.46 | 2021 | |
| Sun Pharmaceutical Industries INC. | $27.01 | 2022-2025 | |
| Johnson & Johnson Vision Care, INC. | $22.30 | 2024 | |
| Novartis Pharmaceuticals Corporation | $15.88 | 2023 | |
| Kala Pharmaceuticals, INC. | $15.27 | 2019 | |
| Abbvie INC. | $14.56 | 2024 | |
| Maculogix, INC. | $14.37 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $13.56 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Collin Rush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.